Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 2003

View Archived Issues

SARS in the intellectual portfolios

CDP-870 in active Crohn's disease

Visilizumab reported effective in severe ulcerative colitis

HCT-1026 is better tolerated than flurbiprofen

Good safety and efficacy profile found for lubiprostone in constipation

Sleep improvement induced by eszopiclone in chronic insomniacs

New protein kinase/phosphatase inhibitors and their use for preventing hearing loss

GSK claims orexin receptor antagonists for obesity, sleep disorders and stroke

Pierre Fabre presents novel dopamine D2 receptor modulators in recent patent

Sodium channel blockers isolated by Meiji Seika from Aspergillus

Novel DPP-IV inhibitors in early development at Roche

Alpha2C-adrenoceptor antagonists with utility in Parkinson's disease

Integrin-targeted antitumor agents designed at Scripps Research Institute

New antitumor Ras signaling modulators developed at Morphochem

Ventavis receives positive opinion in Europe

Valcyte completes European mutual recognition procedure for CMV prevention

Safety phase of lactoferrin study completed

Positive final phase II results for MBP-8298 in MS

OctoPlus and CytImmune to develop TNF with gold-based drug delivery system

ThromboGenics completes phase I trial of microplasmin for thromboembolic diseases

Calblock launched in Japan

Chalcones inhibit eosinophil recruitment, degranulation and survival via VCAM-1 inhibition

Novel class of compounds for asthma with antiinflammatory/antiadhesion properties

Selective herpesvirus agent presented by Charterhouse

TD-6424: a semisynthetic glycopeptide with excellent activity against Gram-positive bacteria

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...